Alnylam Pharmaceuticals | ALNY - Operating Expenses



Alnylam Pharmaceuticals reported $789.89M in Operating Expenses for its fiscal quarter ending in June of 2025.


Operating Expenses Change Date
Acadia Pharmaceuticals USD 232.19M 7.16M Jun/2025
Agios Pharmaceuticals USD 139.51M 24.16M Jun/2025
Alnylam Pharmaceuticals USD 789.89M 213.78M Jun/2025
Amgen USD 6.52B 337M Jun/2025
Arrowhead Research USD 193.32M 31.81M Jun/2025
BioMarin Pharmaceutical USD 548.52M 27.27M Jun/2025
Incyte USD 904.7M 56.97M Jun/2025
Ionis Pharmaceuticals USD 312.21M 34.21M Jun/2025
Moderna USD 1.04B 113M Jun/2025
Neurocrine Biosciences USD 541.9M 7M Jun/2025
Novartis USD 9.37B 782M Jun/2025
PTC Therapeutics USD 213.73M 7.86M Jun/2025
Regeneron Pharmaceuticals USD 2.6B 159.1M Jun/2025
Sanofi EUR 8.8B 2.03B Jun/2025
Sarepta Therapeutics USD 495.51M 549.73M Jun/2025
Takeda JPY 922.12B 206.21B Jun/2025
Tectonic Therapeutic USD 22.33M 8.34M Jun/2025
Ultragenyx Pharmaceutical USD 274.38M 7.85M Jun/2025
Vertex Pharmaceuticals USD 1.81B 71.4M Jun/2025
Xencor USD 76.78M 865K Jun/2025